“Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed”: starting from this premise, a group of researchers of the Memorial Sloan Kettering Cancer Center in New York led [more]
A huge gap in the Hellenic Organization for Health Care Services Provision reimbursement system (EOPPY) for cancer biomarkers is causing a lot of trouble for doctors and patients. At the moment the Ministry of health [more]
A research letter just published in the journal Nature by an International group of researchers directed by Grace Collord of the Wellcome Sanger Institute and University of Cambridge, in England, “provides proof-of-principle that it may be possible to develop [more]
Pembrolizumab is the first drug approved by the U.S. Food and Drug Administration for use based on a biomarker (a specific genetic feature) rather than the location in the body where the tumor originated. The drug is indicated [more]
For a disease that has led the field of molecular biology, it is surprising perhaps that so few biomarkers have been identified that can predict a person’s risk of developing cancer. Researchers are now looking [more]
Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours [more]
Treating the right patient with the right therapy at the right time depends on having the right picture of every patient’s key biological markers. A number of initiatives are now springing up across Europe to [more]